Brought to you by 
Sumitomo Dainippon acquires Tolero for $200mm cash plus earn-outs
29 May 2020
Executive Summary
Sumitomo Dainippon Pharma Co. Ltd. is acquiring privately held oncology firm Tolero Pharmaceuticals Inc. for $200mm in cash up front. The deal also includes up to $430mm in earn-outs based on development achievements and $150mm in payments based on net sales.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sumitomo Dainippon acquires Tolero for $200mm cash plus earn-outs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice